STOCK TITAN

Bruker Corporation - BRKR STOCK NEWS

Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.

Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.

The company's operations are categorized into four main segments:

  • BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
  • BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
  • BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
  • Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.

Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.

Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.

Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.

Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) has acquired Prolab Instruments GmbH, a Swiss firm specializing in high-precision low-flow liquid chromatography technology. This acquisition is expected to enhance Bruker’s capabilities in proteomics and metabolomics, integrating Prolab's unique Zirconium™ products, including the Zirconium Qube autosampler and Zirconium Ultra UHPLC systems. Prolab's innovations will improve high-performance mass spectrometry workflows, particularly for single-cell proteomics, validating Bruker's strategy in expanding its analytical solutions portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
-
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) will participate in the 40th annual J.P. Morgan Healthcare Conference, scheduled for January 10-13, 2022. The Company’s Chairman and CEO, Frank Laukien, along with Executive Vice President and CFO, Gerald Herman, will present on January 10 at 9:00 AM EST. A live audio webcast of this presentation will be accessible on the Investor Relations section of Bruker's website, with a replay available for 30 days post-event. Bruker focuses on high-performance scientific instruments, enhancing life sciences research and diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
conferences
-
Rhea-AI Summary

Bruker has launched the JPK NanoWizard® V BioAFM, advancing atomic force microscopy for life sciences. This automated system integrates seamlessly with optical microscopes, facilitating rapid mechanobiological measurements from sub-molecular to cellular scales. Key features include enhanced speed, resolution, and user-friendly automation, promoting long-term experiments. Experts believe this innovation could greatly enhance the understanding of cellular processes. Bruker aims to leverage its decade-long experience in quantitative nanomechanics to empower researchers in the biomedical field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) has completed a private placement of 10-year senior notes totaling $500 million to enhance financial flexibility and support growth initiatives. The issuance includes 300 million Swiss Franc 0.88% Series A senior notes and 150 million Euro 1.03% Series B senior notes, both due December 8, 2031. The funds will be used for general corporate purposes, including repaying maturing debts. The financing capitalizes on favorable interest rates, locking in fixed costs for the next decade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.51%
Tags
none
-
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) announced its CE-IVD marked FluoroType® SARS-CoV-2 varID Q PCR assay, capable of detecting all major variants of SARS-CoV-2, including Omicron (B.1.1.529). The assay identifies key S-gene mutations associated with Omicron and provides viral load results in less than 4 hours. It is validated for use with the FluoroCycler® XT thermocycler and supports automated extraction via the GenoXtract® fleXT system. Bruker’s other SARS-CoV-2 assays are also expected to detect the Omicron variant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) announced its acquisition of MOLECUBES NV, enhancing its nuclear molecular imaging (NMI) capabilities. This strategic move aims to expand Bruker's preclinical imaging portfolio with the modular benchtop CUBES™ systems, expected to accelerate NMI adoption in medical and biopharma sectors. MOLECUBES generated approximately Euro 5 million in FY 2020 revenue and will operate within Bruker's BioSpin division, aiming for synergies in research and development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) has announced significant advancements in 4D proteomics workflows, highlighted during the HUPO Reconnect 2021 virtual congress. They introduced a co-marketing agreement with Cellenion for the innovative cellenONE® system, enhancing automation in single-cell proteomics. Additionally, the partnership with Seer enables unprecedented detection of over 3,000 protein groups from human plasma using the Proteograph™ Product Suite. Bruker also expanded its collaboration with PreOmics to showcase the BeatBox™ technology for efficient tissue homogenization, improving proteomic analysis speed and yield.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) has announced a quarterly cash dividend of $0.04 per share, scheduled for payment on December 17, 2021, to stockholders of record as of December 1, 2021.

The Board also approved an increase in the annual cash dividend from $0.16 to $0.20 per share, with payments commencing in March 2022, contingent upon quarterly Board approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
dividends
-
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) will take part in the 2021 Jefferies London Healthcare Conference on November 16, 2021, at 12:20 PM GMT. Gerald Herman, Executive Vice President & Chief Financial Officer, will lead an analyst-moderated Q&A session. A live audio webcast can be accessed via the company's Investor Relations website at https://ir.bruker.com. A replay will be available for 30 days post-event in the 'Events & Presentations' section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
Rhea-AI Summary

Bruker Corporation (Nasdaq: BRKR) announced major advancements in its mass spectrometry capabilities at the 69th ASMS meeting in Philadelphia. The new CCS-enabled technologies for the timsTOF Pro 2, timsTOF fleX, and timsTOF SCP systems enhance proteomics workflows with rapid, high-sensitivity analysis. Key features include the identification of over 8,000 cell lysate proteins, a new OligoQuest software for RNA analysis, and the SCiLS autopilot for automated mass spectrometry imaging. These innovations aim to improve proteomics research, particularly in cancer biology and therapeutic development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none

FAQ

What is the current stock price of Bruker Corporation (BRKR)?

The current stock price of Bruker Corporation (BRKR) is $57 as of December 20, 2024.

What is the market cap of Bruker Corporation (BRKR)?

The market cap of Bruker Corporation (BRKR) is approximately 8.7B.

What does Bruker Corporation specialize in?

Bruker Corporation specializes in analytical instrumentation, offering solutions in magnetic resonance, mass spectrometry, X-ray analysis, and superconducting technologies.

How is Bruker Corporation structured?

Bruker operates in four main segments: BSI BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST).

Where does Bruker generate most of its revenue?

The majority of Bruker's revenue is generated from the Asia Pacific region.

How many employees does Bruker Corporation have?

Bruker Corporation employs over 6,500 people globally.

What industries does Bruker serve?

Bruker serves the life sciences, pharmaceutical, biotechnology, and industrial production sectors.

What recent advancements has Bruker made?

Bruker has made significant advancements in mass spectrometry and has formed key partnerships with leading pharmaceutical and biotechnology firms.

What is BSI BioSpin known for?

BSI BioSpin is known for its magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.

Why are Bruker's technologies important in industrial production?

Bruker's instruments ensure quality and process reliability, which are critical for precision and performance in industrial production.

What is the BEST segment of Bruker Corporation?

BEST, or Bruker Energy & Supercon Technologies, provides superconducting materials and devices for the energy, science, and healthcare sectors.

How does Bruker Corporation contribute to scientific research?

Bruker develops state-of-the-art technologies that assist scientists and researchers in addressing complex analytical questions with precision.

Bruker Corporation

Nasdaq:BRKR

BRKR Rankings

BRKR Stock Data

8.72B
103.19M
31.92%
79.77%
1.99%
Medical Devices
Laboratory Analytical Instruments
Link
United States of America
BILLERICA